{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:58:46Z","timestamp":1648745926533},"reference-count":70,"publisher":"Edizioni Minerva Medica","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Panminerva Med"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.23736\/s0031-0808.20.04141-5","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T08:48:59Z","timestamp":1612514939000},"source":"Crossref","is-referenced-by-count":0,"title":["Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma"],"prefix":"10.23736","volume":"63","author":[{"given":"Alessandra","family":"ROMANO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"SANTORO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"CONTICELLO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"SIRAGUSA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"DI RAIMONDO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"MARTINELLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"CERCHIONE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17149","reference":[{"key":"10.23736\/S0031-0808.20.04141-5_ref001","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858613"},{"key":"10.23736\/S0031-0808.20.04141-5_ref002","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.018"},{"key":"10.23736\/S0031-0808.20.04141-5_ref003","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00911-4"},{"key":"10.23736\/S0031-0808.20.04141-5_ref004","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00699"},{"key":"10.23736\/S0031-0808.20.04141-5_ref005","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3160"},{"key":"10.23736\/S0031-0808.20.04141-5_ref006","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-264333"},{"key":"10.23736\/S0031-0808.20.04141-5_ref007","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06921.x"},{"key":"10.23736\/S0031-0808.20.04141-5_ref008","first-page":"1","article-title":"Newly Diagnosed Myeloma in 2020","volume":"40","author":"Moreau P","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.23736\/S0031-0808.20.04141-5_ref009","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00685"},{"key":"10.23736\/S0031-0808.20.04141-5_ref010","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099358"},{"key":"10.23736\/S0031-0808.20.04141-5_ref011","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16095"},{"key":"10.23736\/S0031-0808.20.04141-5_ref012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8164"},{"key":"10.23736\/S0031-0808.20.04141-5_ref013","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0209-7"},{"key":"10.23736\/S0031-0808.20.04141-5_ref014","first-page":"1243","article-title":"Current management and emerging treatment strategies for multiple myeloma","volume":"60","author":"Lei M","year":"2019","journal-title":"Rinsho Ketsueki"},{"key":"10.23736\/S0031-0808.20.04141-5_ref015","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12205"},{"key":"10.23736\/S0031-0808.20.04141-5_ref016","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.14"},{"key":"10.23736\/S0031-0808.20.04141-5_ref017","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23933"},{"key":"10.23736\/S0031-0808.20.04141-5_ref018","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099341"},{"key":"10.23736\/S0031-0808.20.04141-5_ref019","doi-asserted-by":"publisher","DOI":"10.7150\/jca.8541"},{"key":"10.23736\/S0031-0808.20.04141-5_ref020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.7172"},{"key":"10.23736\/S0031-0808.20.04141-5_ref021","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.101"},{"key":"10.23736\/S0031-0808.20.04141-5_ref022","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2014.219","article-title":"Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival","volume":"29","author":"Ferrero S","year":"2015","journal-title":"Leukemia"},{"key":"10.23736\/S0031-0808.20.04141-5_ref023","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/CMAR.S212455","article-title":"Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide\/Bortezomib\/Ascorbic Acid\/Dexamethasone (ABCD) Regimen Compared to Bortezomib\/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients","volume":"12","author":"Qian W","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.23736\/S0031-0808.20.04141-5_ref024","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bmt.2008.384","article-title":"Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study","volume":"43","author":"Uy GL","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.23736\/S0031-0808.20.04141-5_ref025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00277-011-1298-9","article-title":"Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial","volume":"91","author":"Kim HJ","year":"2012","journal-title":"Ann Hematol"},{"key":"10.23736\/S0031-0808.20.04141-5_ref026","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial","volume":"121","author":"Mellqvist UH","year":"2013","journal-title":"Blood"},{"key":"10.23736\/S0031-0808.20.04141-5_ref027","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ejh.13281","article-title":"Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials","volume":"103","author":"Straka C","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.23736\/S0031-0808.20.04141-5_ref028","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0253-9"},{"key":"10.23736\/S0031-0808.20.04141-5_ref029","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117457"},{"key":"10.23736\/S0031-0808.20.04141-5_ref030","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"10.23736\/S0031-0808.20.04141-5_ref031","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408898"},{"key":"10.23736\/S0031-0808.20.04141-5_ref032","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1611-1"},{"key":"10.23736\/S0031-0808.20.04141-5_ref033","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.267"},{"key":"10.23736\/S0031-0808.20.04141-5_ref034","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1579322"},{"key":"10.23736\/S0031-0808.20.04141-5_ref035","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-36"},{"key":"10.23736\/S0031-0808.20.04141-5_ref036","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.55"},{"key":"10.23736\/S0031-0808.20.04141-5_ref037","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30099-5"},{"key":"10.23736\/S0031-0808.20.04141-5_ref038","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"10.23736\/S0031-0808.20.04141-5_ref039","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8506"},{"key":"10.23736\/S0031-0808.20.04141-5_ref040","first-page":"789","article-title":"Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience","volume":"47","author":"Tanimura A","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.23736\/S0031-0808.20.04141-5_ref041","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3163-y"},{"key":"10.23736\/S0031-0808.20.04141-5_ref042","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25392"},{"key":"10.23736\/S0031-0808.20.04141-5_ref043","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"10.23736\/S0031-0808.20.04141-5_ref044","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"10.23736\/S0031-0808.20.04141-5_ref045","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5600-x"},{"key":"10.23736\/S0031-0808.20.04141-5_ref046","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/456037"},{"key":"10.23736\/S0031-0808.20.04141-5_ref047","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2524-8"},{"key":"10.23736\/S0031-0808.20.04141-5_ref048","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112116"},{"key":"10.23736\/S0031-0808.20.04141-5_ref049","first-page":"2021","article-title":"Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du My\u00e9Lome (IFM)","volume":"130","author":"Moreau P","year":"2017","journal-title":"Blood"},{"key":"10.23736\/S0031-0808.20.04141-5_ref050","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205476"},{"key":"10.23736\/S0031-0808.20.04141-5_ref051","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-576256"},{"key":"10.23736\/S0031-0808.20.04141-5_ref052","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0297-2"},{"key":"10.23736\/S0031-0808.20.04141-5_ref053","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007522"},{"key":"10.23736\/S0031-0808.20.04141-5_ref054","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8002"},{"key":"10.23736\/S0031-0808.20.04141-5_ref055","doi-asserted-by":"crossref","unstructured":"Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant. (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) | Blood | American Society of Hematology; 2020 [Internet]. Available from: https:\/\/ashpublications.org\/blood\/article\/132\/Supplement%201\/121\/262862\/Carfilzomib-Lenalidomide-Dexamethasone-KRd [cited 2020, Sep 10].","DOI":"10.1182\/blood-2018-99-112093"},{"key":"10.23736\/S0031-0808.20.04141-5_ref056","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12641"},{"key":"10.23736\/S0031-0808.20.04141-5_ref057","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13994"},{"key":"10.23736\/S0031-0808.20.04141-5_ref058","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"10.23736\/S0031-0808.20.04141-5_ref059","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2509"},{"key":"10.23736\/S0031-0808.20.04141-5_ref060","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0551"},{"key":"10.23736\/S0031-0808.20.04141-5_ref061","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn439"},{"key":"10.23736\/S0031-0808.20.04141-5_ref062","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1"},{"key":"10.23736\/S0031-0808.20.04141-5_ref063","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922"},{"key":"10.23736\/S0031-0808.20.04141-5_ref064","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"10.23736\/S0031-0808.20.04141-5_ref065","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112899"},{"key":"10.23736\/S0031-0808.20.04141-5_ref066","first-page":"397","article-title":"Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02\/HO95 Study","volume":"130","author":"Cavo M","year":"2017","journal-title":"Blood"},{"key":"10.23736\/S0031-0808.20.04141-5_ref067","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"10.23736\/S0031-0808.20.04141-5_ref068","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719888111"},{"key":"10.23736\/S0031-0808.20.04141-5_ref069","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0298-1"},{"key":"10.23736\/S0031-0808.20.04141-5_ref070","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.335"}],"container-title":["Panminerva Medica"],"original-title":[],"link":[{"URL":"https:\/\/www.minervamedica.it\/pdf.php?cod=R41Y2021N01A0013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T08:49:55Z","timestamp":1612514995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.minervamedica.it\/index2.php?show=R41Y2021N01A0013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":70,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.23736\/s0031-0808.20.04141-5","relation":{},"ISSN":["0031-0808","1827-1898"],"issn-type":[{"value":"0031-0808","type":"print"},{"value":"1827-1898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}